Icon
+91 94997 68112
Login Register

EXTINA (nda021738)- (2%)

KETOCONAZOLE NORVIUM BIOSCIENCE
2%
Yes Yes
2018-Oct-19 Expired
None None
None No
EXTINA® Foam is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older.
2 0 2
Total Other Developers 1
Drugs with Suitability No
2% ** ** - - 2
NDA Sales Available Total Generic Sales Available
Yes 2
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******* ****** ******* ****** *************** *** *********** * ********* ***, *******, *******, ****** (***) ***
****** ******* ************ ******* *** *********** ******** ********** ********** *, ******** ** *******, *****, ***** (***) ***
****** ******* ************ ******* *** *********** ******* ** ********** *, ****** ** *******, ******** ** ******* *****, ***** (***) ***

Download GenUS Drug Report

Download GenUS Detailed Report

To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.